Phase 2 Readout
Phase 2 Readout: laromestrocel
- Company
- Longeveron Inc. (LGVN)
- Drug
- laromestrocel
- Indication
- hypoplastic left heart syndrome (HLHS)
Other upcoming events for LGVN
Track this catalyst and more
Get real-time alerts, AI-powered analysis, and full catalyst coverage.